Revenues in 2018-2019
Invest in Personalis
The Company is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response.
The Company designed its NeXT Platform to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover roughly 50 to 500 genes.
According to a 2016 market research report by Grand View Research, the global cancer genomics market is projected to reach $9.22 billion by 2022.
The main factors driving market growth are the increasing prevalence of cancer as well as the adoption of next-generation sequencing for diagnostic and treatment applications in cancer care.
The genome sequencing segment is anticipated to grow at a strong CAGR of 17.5% in the upcoming years due to the benefits this method provides, such as faster and more accurate results.
The company has substantial customer concentration, with a limited number of customers accounting for a substantial portion of 2018 revenues and accounts receivable.
The company faces intense competition and could lose market share to competitors, which could adversely affect business, financial condition, and results of operations.
Tests provided by Personalis may be subject to regulatory action if regulatory agencies determine that these tests do not appropriately comply with statutory and regulatory requirements enforced by the FDA and/or CLIA requirements for quality laboratory testing.
Recent IPOs in Biotech sector:
Guardant Health +105% 3-month return.
Twist Biosciences +65% 3-month return.
Personalis demonstrates significant revenue growth rates (over 300%) YoY, generates positive cash flow from operating activities over the last 2 years, and is active in a promising and fast growing market.
Personalis (PSNL) plans to raise $107 million; its market cap at IPO will equal $480 million ($14-$16 price range). Comparing the company’s performance with the most recent biotech IPOs, the return on investment may exceed 70%.
2-3 weeks before the start of the company publishes information about the opening of trading: financial statements for 3 years, a description of the company's business, plans for the future, as well as the risks that management sees in their own business. We analyze such offers and publish the best ones. Investors apply for deposits. Before the deadline for applications, you can change the request or cancel it.
We submit one large application for the purchase of shares by pre-subscription with reduced price to large investors. The application may be rejected in part or in full. Over the past three years, our applications have been rejected only three times. The next day, or every other day, we'll know at what price and at what percentage the order is executed, and we'll post it on «The my investment page».
The price of shares is rising from the first day due to the demand of investors deprived of the opportunity to buy shares before trading. Most of the stocks we've been recommending buying over the past three years have been starting to trade on the stock exchange at tens of percent higher than the price at which customers bought the shares. There comes a Lock up period when it is forbidden to sell shares purchased by subscription. Typically lasts 3 months.
After the expiration of the Lock Up period, the investment is automatically closed and the investor receives a profit on account of the deduction commissions UT. You can always view the results of your past investments in investment archive.
Although no shares are allowed to be sold during the lock-up period, our traders seek to offer investors fixed profit by way of using various financial instruments, including forwards, options, short positions etc.
From the investor’s point of view this means that he or she may close an investment by paying a certain part of its value (as a rule, approximately 15 percent). This is due to high prices for the instruments which are employed to ensure availability of fixed profit. As such, you shall press any relevant button in the Investor Account as soon as it is active.
The closing procedure is similar to commencement of investment business. You shall file a bid which is executed within a business day by UT. So, your investment is closed at the price currently prevailing on the stock exchange. However, we rarely recommend using this feature, since upon expiry of an applicable lock-up period the average performance is higher.
3 per cent of the share price. This fee is charged as soon as your investment bid is confirmed.
1.75 per cent of the purchase price paid for your shares as soon as trading is closed. This fee is charged upon closure of any relevant investment.
20 per cent of the profit your derive. This fee is charged only if you show positive performance as of the moment any relevant investment is closed.
TO EARLY EXIT
Usually, 15 per cent (depends on the stock exchange environment). It is calculated per each investment individually.
Our risk managers ensure proper support throughout the entire transaction. Moreover, you may call them on +7 495 646-15-57 or 8 800 333-66-81 or visit our office, if a more detailed discussion is needed.
IN THE PROFIT FROM THE FIRST DAY
Such an approach allows it to limit extra risks related to bankruptcy of start-ups and considerably increase profit vs investors purchasing shares on open Market.
LOW ENTRY THRESHOLD
Millions of dollars are required to buy shares on a subscription basis. We have generated a pool of traders and investors which enables any newbie to participate in any transaction as aforesaid by investing just USD50 or more.